Role of tumor necrosis factor alpha in disease using a mouse model of Shiga toxin-mediated renal damage

Infection and Immunity

Volumn 78, Issue 9, 2010, Pages 3689-3699

  Lentz, Erin K ^a   Cherla, Rama P ^a   Jaspers, Valery ^a   Weeks, Bradley R ^b   Tesh, Vernon L ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1BETA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; VEROTOXIN 1; VEROTOXIN 2; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; HISTOPATHOLOGY; KIDNEY INJURY; LETHALITY; MALE; MOUSE; NONHUMAN; PREMEDICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; C3H MOUSE; DISEASE MODEL; DRUG EFFECT; KIDNEY; PATHOLOGY;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; KIDNEY; MALE; MICE; MICE, INBRED C3H; RECOMBINANT PROTEINS; SHIGA TOXIN 1; SHIGA TOXIN 2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956622569     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00616-10     Document Type: Article

References (56)

1. Barrett, T. J., M. E. Potter, and I. K. Wachsmuth. 1989. Bacterial endotoxin both enhances and inhibits the toxicity of Shiga-like toxin II in rabbits and mice. Infect. Immun. 57:3434-3437.
2. Bitzan, M., E. Moebius, K. Ludwig, D. E. Müller-Wiefel, J. Heesemann, and H. Karch. 1991. High incidence of serum antibodies to Escherichia coli O157 lipopolysaccharide in children with hemolytic-uremic syndrome. J. Pediatr. 119:380-385.
3. Boerlin, P., S. A. McEwen, F. Boerlin-Petzold, J. B. Wilson, R. P. Johnson, and C. L. Gyles. 1999. Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J. Clin. Microbiol. 37:497-503.
4. Brigotti, M., D. Carnicelli, E. Ravanelli, A. G. Vara, C. Martinelli, R. R. Alfieri, P. G. Petronini, and P. Sestili. 2007. Molecular damage and induction of proinflammatory cytokines in human endothelial cells exposed to Shiga toxin 1, Shiga toxin 2, and alpha-sarcin. Infect. Immun. 75:2201-2207.
5. Chen, G., E. A. Bridenbaugh, A. D. Akintola, J. M. Catania, V. S. Vaidya, J. V. Bonventre, A. C. Dearman, H. W. Sampson, D. C. Zawieja, R. C. Burghardt, and A. R. Parrish. 2007. Increased susceptibility of aging kidney to ischemic injury: identification of candidate genes changed during aging, but corrected by caloric restriction. Am. J. Physiol. Renal Physiol. 293:F1272-F1281.
6. Cherla, R. P., S.-Y. Lee, P. L. Mees, and V. L. Tesh. 2006. Shiga toxin 1-induced cytokine production is mediated by MAP kinase pathways and translation initiation factor eIF4E in the macrophage-like THP-1 cell line. J. Leukoc. Biol. 79:397-407.
7. Donohue-Rolfe, A., I. Kondova, S. Oswald, D. Hutto, and S. Tzipori. 2000. Escherichia coli O157:H7 strains that express Shiga toxin (Stx) 2 alone are more neurotropic for gnotobiotic piglets than are isotypes producing only Stx1 or both Stx1 and Stx2. J. Infect. Dis. 181:1825-1829.
8. Falguières, T., F. Mallard, C. Baron, D. Hanau, C. Lingwood, B. Goud, J. Salamero, and L. Johannes. 2001. Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent-resistant membranes. Mol. Biol. Cell 12:2453-2468.
9. - mutant of Shigella dysenteriae 1. Infect. Immun. 56:3099-3109.
10. Greatorex, J. S., and G. M. Thorne. 1994. Humoral immune responses to Shiga-like toxins and Escherichia coli 0157 lipopolysaccharide in hemolytic-uremic syndrome patients and healthy subjects. J. Clin. Microbiol. 32:1172-1178.
11. Griener, T. P., G. L. Mulvey, P. Marcato, and G. D. Armstrong. 2007. Differential binding of Shiga toxin 2 to human and murine neutrophils. J. Med. Microbiol. 56:1423-1430.
12. Harrison, L. M., W. C. E. van Haaften, and V. L. Tesh. 2004. Regulation of proinflammatory cytokine expression by Shiga toxin 1 and/or lipopolysaccharides in the human monocytic cell line THP-1. Infect. Immun. 72:2618-2627.
13. Honda, N., A. Hishida, K. Ikuma, and K. Yonemura. 1987. Acquired resistance to acute renal failure. Kidney Int. 31:1233-1238. (Pubitemid 17090487)
14. Hurley, B. P., M. Jacewicz, C. M. Thorpe, L. L. Lincicome, A. J. King, G. T. Keusch, and D. W. K. Acheson. 1999. Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cells. Infect. Immun. 67:6670-6677.
15. Karpman, D., A. Andreasson, H. Thysell, B. S. Kaplan, and C. Svanborg. 1995. Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Pediatr. Nephrol. 9:694-699.
16. Karpman, D., A. Håkansson, M.-T. R. Perez, C. Isaksson, E. Carlemalm, A. Caprioli, and C. Svanborg. 1998. Apoptosis of renal cortical cells in the hemolytic-uremic syndrome: in vivo and in vitro studies. Infect. Immun. 66:636-644.
17. Kawano, K., M. Okada, T. Haga, K. Maeda, and Y. Goto. 2008. Relationship between pathogenicity for humans and stx genotype in Shiga toxin-producing Escherichia coli serotype O157:H7. Eur. J. Clin. Microbiol. Infect. Dis. 27:227-231.
18. Keepers, T. R., L. K. Gross, and T. G. Obrig. 2007. Monocyte chemoattractant protein 1, macrophage inflammatory protein 1 alpha, and RANTES recruit macrophages to the kidney in a mouse model of hemolytic-uremic syndrome. Infect. Immun. 75:1229-1236.
19. Keepers, T. R., M. A. Psotka, L. K. Gross, and T. G. Obrig. 2006. A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. J. Am. Soc. Nephrol. 17:3404-3414.
20. Kimura, T., S. Tani, Y. Matsumoto, and T. Takeda. 2001. Serum amyloid P component is the Shiga toxin 2-neutralizing factor in human blood. J. Biol. Chem. 276:41576-41579.
21. Koster, F. T., V. Boonpucknavig, S. Sujaho, R. H. Gilman, and M. M. Rahaman. 1984. Renal histopathology in the hemolytic-uremic syndrome following shigellosis. Clin. Nephrol. 21:126-133.
22. Lee, S.-Y., M.-S. Lee, R. P. Cherla, and V. L. Tesh. 2008. Shiga toxin 1 induces apoptosis through the endoplasmic reticulum stress response in human monocytic cells. Cell Microbiol. 10:770-780.
23. López, E. L., M. M. Contrini, S. Devoto, M. F. de Rosa, M. G. Graña, M. H. Genero, C. Canepa, H. F. Gomez, and T. G. Cleary. 1995. Tumor necrosis factor concentrations in hemolytic uremic syndrome patients and children with bloody diarrhea in Argentina. Pediatr. Infect. Dis. J. 14:594-598.
24. Louise, C. B., and T. G. Obrig. 1991. Shiga toxin-associated hemolyticuremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect. Immun. 59:4173-4179.
25. Louise, C. B., and T. G. Obrig. 1995. Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells. J. Infect. Dis. 172:139-1401.
26. Ludwig, K., M. Bitzan, S. Zimmermann, M. Kloth, H. Ruder, and D. E. Müller-Wiefel. 1996. Immune response to non-O157 Vero toxin-producing Escherichia coli in patients with hemolytic uremic syndrome. J. Infect. Dis. 174:1028-1039.
27. Matussek, A., J. Lauber, A. Bergau, W. Hansen, M. Rohde, K. E. Dittmar, M. Gunzer, M. Mengel, P. Gatzlaff, M. Hartmann, J. Buer, and F. Gunzer. 2003. Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. Blood 102:1323-1332.
28. Nakajima, H., N. Kiyokawa, Y. U. Katagiri, T. Taguchi, T. Suzuki, T. Sekino, K. Mimori, T. Ebata, M. Saito, H. Nakao, T. Takeda, and J. Fujimoto. 2001. Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance. J. Biol. Chem. 276:42915-42922.
29. Nath, K. A., G. Balla, G. M. Vercellotti, J. Balla, H. S. Jacob, M. D. Levitt, and M. E. Rosenberg. 1992. Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. J. Clin. Investig. 90:267-270.
30. Obrig, T. G., T. P. Moran, and J. E. Brown. 1987. The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem. J. 244: 287-294.
31. Orth, D., K. Grif, A. B. Khan, A. Naim, M. P. Dierich, and R. Würzner. 2007. The Shiga toxin genotype rather than the amount of Shiga toxin or cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. Diagn. Microbiol. Infect. Dis. 59:235-242.
32. Palermo, M., F. Alves-Rosa, C. Rubel, G. C. Fernández, G. Fernández- Alonso, F. Alberto, M. Rivas, and M. Isturiz. 2000. Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose-dependent opposite effects on Shiga toxin-2 lethality. Clin. Exp. Immunol. 119:77-83.
33. Proulx, F., E. G. Seidman, and D. Karpman. 2001. Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. Pediatr. Res. 50:163-171.
34. Ramegowda, B., J. E. Samuel, and V. L. Tesh. 1999. Interaction of Shiga toxins with human brain microvascular endothelial cells: cytokines as sensitizing agents. J. Infect. Dis. 180:1205-1213.
35. Ramegowda, B., and V. L. Tesh. 1996. Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines. Infect. Immun. 64:1173-1180.
36. Richardson, S. E., M. A. Karmali, L. E. Becker, and C. R. Smith. 1988. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin- producing Escherichia coli infections. Hum. Pathol. 19:1102-1108.
37. Rutjes, N. W. P., B. A. Binnington, C. R. Smith, M. D. Maloney, and C. A. Lingwood. 2002. Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse model. Kidney Int. 62:832-845.
38. Sandvig, K. 2001. Shiga toxins. Toxicon 39:1629-1635.
39. Sandvig, K., S. Grimmer, S. U. Lauvrak, M. L. Torgersen, G. Skretting, B. van Deurs, and T. G. Iversen. 2002. Pathways followed by ricin and Shiga toxin into cells. Histochem. Cell Biol. 117:131-141.
40. Sauter, K. A., A. R. Melton-Celsa, K. Larkin, M. L. Troxell, A. D. O'Brien, and B. E. Magun. 2008. Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody. Infect. Immun. 76:4469-4478.
41. Smith, W. E., A. V. Kane, S. T. Campbell, D. W. Acheson, B. H. Cochran, and C. M. Thorpe. 2003. Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells. Infect. Immun. 71:1497-1504.
42. Stearns-Kurosawa, D. J., V. Collins, S. Freeman, V. L. Tesh, and S. Kurosawa. 2010. Distinct physiologic and inflammatory responses elicited in baboons after challenge with Shiga toxin type 1 or 2 from enterohemorrhagic Escherichia coli. Infect. Immun. 78:2497-2504.
43. Stricklett, P. K., A. K. Hughes, Z. Ergonul, and D. E. Kohan. 2002. Molecular basis for up-regulation by inflammatory cytokines of Shiga toxin 1 cytotoxicity and globotriaosylceramide expression. J. Infect. Dis. 186:976-982.
44. Strockbine, N. A., L. R. M. Marques, J. W. Newland, H. Williams-Smith, R. K. Holmes, and A. D. O'Brien. 1986. Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect. Immun. 53:135-140.
45. Suffredini, A. F., and N. P. O'Grady. 1999. Pathophysiological responses to endotoxins in humans, p. 817-830. In H. Brade, S. M. Opal, S. N. Vogel, and D. C. Morrison (ed.), Endotoxin in health and disease. Marcel Dekker, Inc., New York, NY.
46. Suzuki, A., H. Doi, F. Matsuzawa, S. Aikawa, K. Takiguchi, H. Kawano, M. Hayashida, and S. Ohno. 2000. Bcl-2 antiapoptotic protein mediates verotoxin II-induced cell death: possible association between Bcl-2 and tissue failure by E. coli O157:H7. Genes Dev. 14:1734-1740.
47. Tarr, P. I., C. A. Gordon, and W. L. Chandler. 2005. Shiga-toxin- producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073-1086.
48. Taylor, F. B., Jr., V. L. Tesh, L. DeBault, A. Li, A. C. Chang, S. D. Kosanke, T. J. Pysher, and R. L. Siegler. 1999. Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am. J. Pathol. 154:1285-1299.
49. Tesh, V. L. 2010. Induction of apoptosis by Shiga toxins. Fut. Microbiol. 5:431-453.
50. Tesh, V. L., J. A. Burris, J. W. Owens, V. M. Gordon, E. A. Wadolkowski, A. D. O'Brien, and J. E. Samuel. 1993. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect. Immun. 61:3392-3402.
51. Tesh, V. L., B. Ramegowda, and J. E. Samuel. 1994. Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages. Infect. Immun. 62:5085-5094.
52. Thorpe, C. M., B. P. Hurley, L. L. Lincicome, M. S. Jacewicz, G. T. Keusch, and D. W. Acheson. 1999. Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells. Infect. Immun. 67:5985-5993.
53. van Setten, P. A., V. W. M. van Hinsbergh, T. J. A. N. van der Velden, N. C. A. J. van de Kar, M. Vermeer, J. D. Mahan, K. J. M. Assmann, L. P. W. J. van den Heuvel, and L. A. H. Monnens. 1997. Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int. 51:1245-1256.
54. Wadolkowski, E. A., L. M. Sung, J. A. Burris, J. E. Samuel, and A. D. O'Brien. 1990. Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II. Infect. Immun. 58:3959-3965.
55. Yamasaki, C., Y. Natori, X. T. Zeng, M. Ohmura, S. Yamasaki, and Y. Takeda. 1999. Induction of cytokines in a human colon epithelial cell line by Shiga toxin 1 (Stx1) and Stx2 but not by non-toxic mutant Stx1 which lacks N-glycosidase activity. FEBS Lett. 442:231-234. (Pubitemid 29070839)
56. Zager, R. A., A. C. M. Johnson, S. Y. Hanson, and S. Lund. 2006. Acute nephrotoxic and obstructive injury primes the kidney to endotoxin-driven cytokine/chemokine production. Kidney Int. 69:1181-1188.